Advertisement

World Journal of Surgery

, Volume 14, Issue 1, pp 94–99 | Cite as

Group I pepsinogen for early detection of gastric cancer recurrence after total gastrectomy

  • Masashi Kodama
  • Kenji Koyama
  • Yukio Tsuburaya
  • Kouichi Ishikawa
  • Hirofumi Koyama
  • Tomio Narisawa
  • Yoshitaka Uesaka
Original Scientific Reports

Abstract

Group I pepsinogen (PG-I) staining was performed in the gastric carcinoma tissues of 75 patients by the peroxidase-antiperoxidase (PAP) method, 44 cases (59%) of which were positive for PG-I, suggesting that they were PG-I-producing gastric carcinomas. Type IV gastric carcinoma by the Borrmann classification and/or poorly-differentiated adenocarcinoma were positive for PG-I in high incidence. Serum and urinary levels of PG-I were determined by the Pepsinogen I Radioimmunoassay Kit in patients with gastric carcinoma who underwent total gastrectomy. The levels of PG-I declined remarkably or disappeared at 1 week after curative surgery. Changes of serum PG-I levels after total gastrectomy were observed in 9 patients with PG-I-producing gastric carcinomas, 7 of whom died of recurrence. The PG-I values became elevated with recurrence in 5 of them and the values increased with the passage of time. In contrast, no substantial changes in PG-I levels occurred in patients with no recurrence. These results suggest that PG-I is useful for the early detection of recurrent disease after total gastrectomy in patients with PG-I-producing gastric carcinomas.

Keywords

Carcinoma Gastric Cancer Adenocarcinoma Early Detection Gastric Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

Des prélèvements tissulaires de cancer gastrique chez 75 patients one été testés à la recherche de pepsinogène du groupe I (PG-I) par la méthode peroxydase-antiperoxydase. L'examen était positif dans 44 cas (59%), suggérant que ces cancers produisaient le PG-I. Les cancers gastriques du type IV de la classification de Borrmann et/ou les adénocarcinomes peu différenciés produisaient également le PG-I avec une incidence élevée. Le taux de PG-I dans le sérum et dans les urines a été déterminé par la méthode d'immunofluorescence chez les patients ayant subi une gastrectomie totale pour un cancer gastrique. Le taux de PG-I a diminué de façon importante ou a complètement disparu une semaine après l'intervention à visée curative. Des variations sériques de PG-I ont été observées chez 9 patients dont 7 sont morts de récidive. Le taux de PG-I était élevé chez 5 des 7 patients. Par contre, le taux de PG-I n'a jamais varié chez les patients n'ayant pas eu de récidive. Ces résultats suggèrent, dans la surveillance des patients ayant un cancer produisant le PG-I, que le dosage de PG-I est utile pour détecter la récidive.

Resumen

Se realizó la tinción de PG-I en tejidos de carcinoma gástrico de 75 pacientes por el medio de la peroxidasa-antiperoxidasa (PAP); 44 casos (59%) resultaron positivos para PG-I, lo cual sugiere que eran carcinomas gástricos productores de PG-I. Los carcinomas tipo IV de la clasificación de Borrmann y/o los adenocarcinomas pobremente diferenciados fueron positivos para PG-I con una alta frecuencia. Se realizaron determinaciones de los nivelés séricos y urinarios de PG-I por medio del Pepsinogen I Radioimmunoassay Kit en pacientes con carcinoma gástrico sometidos a gastrectomía total. El nivel de PG-I declinó en forma notoria o desapareció a la semana después de efectuada cirugía curativa. Se observaron cambios en los niveles séricos de PG-I después de la gastrectomía total en 9 pacientes con carcinomas gástricos productores de PG-I, 7 de los cuales murieron por recurrencia. Los niveles se elevaron en forma coincidente con la recurrencia en 5 de ellos y se incrementaron con el transcurso del tiempo. Por el contrario, no se observaron cambios sustanciales en los niveles de PG-I en los pacientes libres de recurrencia. Estos resultados sugieren que el PG-I es de utilidad en la detección temprana de enfermedad recurrente después de gastrectomía total en pacientes con carcinomas gástricos productores de PG-I.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Takahashi, T., Kodama, M., Yamaguchi, T., Kida, K.: The existence of group I pepsinogen (PGI) after total gastrectomy. Gastroenterology86:1274, 1984Google Scholar
  2. 2.
    Kodama, M., Tsuburaya, Y., Kodama, Y., Kotanagi, H., Ishikawa, K., Narisawa, T., Koyama, K., Yamaguchi, T., Takahashi, T.: Production of group I pepsinogen by gastric carcinoma. Tohoku J. Exp. Med.148:239, 1986Google Scholar
  3. 3.
    Ichinose, M., Miki, K., Furuhata, C., Kageyama, T., Niwa, H., Oka, H., Oda, T., Matsushima, T., Takahashi, K.: Radioimmunoassay of group I pepsinogen (PGI) in human serum with reference to serum PGI concentrations in normal controls, patients with gastroduodenal disorders and renal failure cases. Jpn. J. Gastroenterol.79:1098, 1982Google Scholar
  4. 4.
    Miwa, K.: The report of treatment results of stomach carcinoma in Japan.24:111, 1986Google Scholar
  5. 5.
    Samloff, I.M.: Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology61:185, 1971Google Scholar
  6. 6.
    Samloff, I.M., Townes, P.: Electrophoretic heterogeneity and relationship of pepsinogens in human urine, serum and gastric mucosa. Gastroenterology58:462, 1970Google Scholar
  7. 7.
    Samloff, I.M.: Slow moving protease and the seven pepsinogens. Gastroenterology57:659, 1969Google Scholar
  8. 8.
    Samloff, I.M.: Immunologic studies of human group I pepsinogens. J. Immunol.106:962, 1971Google Scholar
  9. 9.
    Kodama, M., Takahashi, T., Kida, K., Yamaguchi, T.: Group I Pepsinogen (PGI) in the serum and the urine after total gastrectomy. J. Jpn. Surg. Soc.85:675, 1984Google Scholar
  10. 10.
    Mangla, J.C., Kim, Y., Guarasci, G., Schenk, E.A.: Pepsinogens in epithelium of Barrett's esophagus. Gastroenterology65:949, 1973Google Scholar
  11. 11.
    Ikeda, K., Sannohe, Y., Murayama, H., Ikeda, R., Inutsuka, S.: Heterotopic gastric mucosa in the duodenum—reaction to congo red under fiberscopic observation. Endoscopy14:168, 1982Google Scholar
  12. 12.
    Lee, S.M., Mosenthal, W.T., Weismann, R.E., Hanover, N.H.: Tumorous heterotopic gastric mucosa in the small intestine. Arch. Surg.100:619, 1970Google Scholar
  13. 13.
    Wolfe, M.: Heterotopic gastric epithelium in the rectum: A case report of three new cases with a review of 87 cases of gastric heterotopia in the alimentary canal. Am. J. Clin. Pathol.55:604, 1971Google Scholar
  14. 14.
    Lieber, A.F.: Aberrant pyloric gland in regional ileitis. Arch. Pathol.51:205, 1951Google Scholar
  15. 15.
    Ming, S., Simon, M., Tandon, B.: Gross gastric metaplasia of ileum after regional ileitis. Gastroenterology44:63, 1963Google Scholar
  16. 16.
    Samloff, L.M., Liebman, W.N.: Cellular localization of the group I pepsinogens in human stomach. Gastroenterology65:36, 1973Google Scholar
  17. 17.
    Ikeda, E., Kojima, O., Okutani, T., Kitagawa, N., Majima, T., Uehara, Y., Nishioka, B., Fujita, Y., Majima, S.: Relationship of prognosis of gastric cancer patients to the staining for carcinoembryonic antigen (CEA) in gastric cancer. Jpn. Gastroenterol. Surg.16:1638, 1983Google Scholar

Copyright information

© Société Internationale de Chirurgie 1990

Authors and Affiliations

  • Masashi Kodama
    • 1
  • Kenji Koyama
    • 1
  • Yukio Tsuburaya
    • 1
  • Kouichi Ishikawa
    • 1
  • Hirofumi Koyama
    • 1
  • Tomio Narisawa
    • 1
  • Yoshitaka Uesaka
    • 1
  1. 1.First Department of Surgery and First Department of PathologyAkita University School of MedicineAkitaJapan

Personalised recommendations